**Supplementary Table S5. Association between *SChLAP1* expression and clinicopathological factors in glioma**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Variables | No. of  cases | *SChLAP1* expression  low high | | *P* value |
| **Age (year)** |  |  |  |  |
| <60 | 91 | 34 | 57 | 0.1311 |
| ≥60 | 21 | 4 | 17 |
| **Gender** |  |  |  |  |
| Male | 63 | 23 | 40 | 0.5515 |
| Female | 49 | 15 | 34 |
| ***IDH1* Status** |  |  |  |  |
| WT | 51 | 12 | 39 | 0.0450\*  0.0546  <0.001\*\*\* |
| MT | 61 | 26 | 35 |
| ***ATRX* Status**  Positive  Negative  **WHO Grade**  II  III  IV  LGG  HGG | 76  36  30  31  51  30  82 | 21  17  19  9  10  19  19 | 55  19  11  22  41  11  63 |

WT: wild type; MT: mutant; LGG: low grade glioma, WHO II; HGG: high grade glioma, WHO III-IV. Fisher’s exact test or Chi-square test: \*= *P* < 0.05; \*\*\*= *P* < 0.001.